bioRxiv · 10.1101/2025.04.01.646433
Pre-Clinical Evaluation of a Novel Immunomodulator: a potential immunotherapy for coronaviral disease
Abstract
At present, no unifying animal study to quantify the effect of PI on innate immunity in animals has been reported. This study quantifies the effect of PI in mice and THP-1 cells using a multi-disciplinary approach employing flow cytometry to measure immune function and mass spectroscopy to identify metabolomic profiles of treated cells. For proof of principle, a case study was conducted to examine the potential benefit of administering PI to improve outcomes of a feline leukemia-positive cat that also contracted the effusive form of FIP. Our results indicate that quantifiable cellular and metabolic markers result from PI treatment and can be used to establish a platform measuring the efficacy of PI in modulating the innate immune system.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Lee, I., Desai, A., Berdis, A. J., Patil, A., Xu, Y., Pozza-Adams, K.. 2025-04-02. Pre-Clinical Evaluation of a Novel Immunomodulator: a potential immunotherapy for coronaviral disease. https://doi.org/10.1101/2025.04.01.646433
Cite the original work for its findings. Save a collection to share your selection of sources.